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Aims: The aim of this study was to compare the complications of pregnancy, childbirth and 34 
neonatal in women with different forms of polycystic ovary syndrome (PCOS) with healthy 35 
women. 36 
Methods: A prospective study from the beginning to the end of pregnancy for 41 pregnant 37 
women with PCOS (case) and 49 healthy pregnant women (control) was completed. Based on 38 
the presence or absence of menstrual dysfunction (M), hyperandrogenism (HA) and polycystic 39 
ovaries (PCO) on ultrasound, the PCOS (case) group were divided into three phenotypes (HA + 40 
PCO (n=22), M + PCO (n=9), HA + M + PCO (n=10).  41 
Result: Pre-eclampsia, gestational diabetes and lower birth weight among newborns were 42 
significantly higher in the PCOS case group compared to the control group especially in the 43 
phenotype HA + M + PCO (P<0.05). High BMI (β=2.40; P=0.03) was the strongest predictor of 44 
pre-eclampsia in patients with PCOS. High androgen levels (free androgen index) (β=13.71, 45 
3.02; P<0.05), was the strongest predictor of developing diabetes during pregnancy and reduced 46 
birth weight baby, respectively. 47 
Conclusion: The results of the present study suggest that PCOS is a risk factor for adverse 48 
pregnancy and neonatal outcomes including gestational diabetes, pre-eclampsia and reduced 49 
weight babies.  50 






Polycystic ovary syndrome (PCOS) is a common and complex endocrine disorder that affects 55 
women of reproductive age (1). The Rotterdam criteria suggest that are three detectable 56 
phenotypes in women presenting with PCOS symptoms: anovulation/menstrual irregularities 57 
with polycystic ovary with ultrasound (M + PCO), hyperandrogenism with polycystic ovary with 58 
ultrasound (HA + PCO) and hyperandrogenism with anovulation/menstrual irregularities and 59 
polycystic ovary (M + HA + PCO). The prevalence of PCOS in the studies was estimated 2.2-60 
26% in developed countries (2-5). Complications associated with polycystic ovary syndrome can 61 
occur across the life span for women (6). In this study, we considered complications and 62 
outcomes associated with pregnancy, childbirth and neonatal period. Prospective and 63 
retrospective studies have been reported PCOS as a risk factor for increased incidence of 64 
pregnancy complications (7-9). Pregnancy complications in the first trimester in women with 65 
PCOS include hyperemesis gravidarum, abortion and fetal abnormalities (10-12). 66 
 67 
Pregnant women with PCOS are at increased risk of gestational diabetes as pregnancy is one of 68 
the predisposing factors to increased insulin resistance that may result in gestational diabetes 69 
during pregnancy. In addition, insulin resistance is higher in women with PCOS who are 70 
overweight (25-70% of women with PCOS has insulin resistance). Further potential risks include  71 
gestational diabetes, preeclampsia, gestational hypertension, premature birth, mortality and an 72 
increased risk of hospitalization in the intensive care unit for newborns in pregnant patients with 73 
PCOS (13). In the only study to assess pregnancy and neonatal outcomes in women with PCOS 74 
with different phenotypes (n=97) compared to healthy pregnant women (n=73), Palomba et al.  75 
reported significant differences in the prevalence of abortion, gestational hypertension, 76 
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gestational diabetes, pre-delivery bleeding between the phenotypes of PCOS and control groups, 77 
respectively. In Palomba et al.(14) study, there were no significant differences between groups in 78 
terms of incidence of fetal malformations, placental abruption and Apgar score. And in a meta-79 
analysis, Qin et al.(15), suggested that the effects of pregnancy and neonatal outcomes among 80 
phenotypes of PCOS are unknown and requires further studies in this regard. 81 
Given the prevalence of PCOS in Iran (1.7-6.14%) and the lack of adequate information on 82 
pregnancy and neonatal outcomes in women with different phenotypes of PCOS, this study 83 
aimed to evaluate the results of pregnancy, childbirth and neonatal outcomes in women with 84 
different PCOS phenotypes compared to healthy pregnant women. 85 
 86 
Methods  87 
Design and data collection 88 
The present study is a prospective cohort study using convenience sampling. In this study 89 
exposure was having PCOS and not exposure was no PCOS for investigate how adverse obstetric 90 
outcomes vary. Therefore, the exposure group included women with PCOS referred to an 91 
infertility clinic in Shahid Beheshti hospital in Kashan, Isfahan, Iran from April 2014 to April 92 
2016. This is the only referral clinic in Kashan. The non exposure group comprised healthy 93 
women who had been referred to this clinic because of male factor infertility. After presenting 94 
the purpose of the study to suitable participants who met the inclusion criteria, a written consent 95 
was obtained from each volunteer who were asked to complete the three measures. 96 
Inclusion criteria were Desire to participate in the study, being 15–40 years of age, Married, 97 
Absence   of   non-classic   adrenal   hyperplasia,   thyroid   dysfunction,   hyperprolactinemia, 98 
Non-smoking, No problems in speaking or listening, Iranian, First pregnancy, Spontaneous 99 
pregnancy, Not having uterus malformations, Not having chronic diseases, Having  two  of  the  100 
following  Rotterdam  diagnostic  criteria:  101 
 1)  Polycystic  ovaries  visualized  on ultrasound scan (presence of 12 follicles or more in one or 102 
both ovaries and/or increased ovarian volume i.e., >10 ml),  103 
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2) clinical signs of hyperandrogenism (hirsutism score based on hirsutism score greater than 7 or 104 
obvious acne) , 105 
 3) having an interval between menstrual periods >35 days and/or  amenorrhea,  defined  as  the  106 
absence  of  vaginal  bleeding  for  at  least  6  months  (i.e.  199 days).  107 
According to Palomba et al.(14), P1:46.2%, P2:85.5%, α=0.05 and β=0.20, sample size was 108 
estimated at 40 couples per group. 109 
Hormonal profiles were sought in both groups before pregnancy.  The participants were followed 110 
from 7 weeks (6-10 weeks) of pregnancy until after delivery. The pregnancy visit intervals were 111 
according to Iran Ministry of Health guideline.  112 
 113 
Measures 114 
1. Menstrual history: women were asked about the interval of two menstrual cycles in the last 12 115 
months; their menstrual cycles were classified as following: <21 days, 21-34-34-60, >199 days 116 
and irregular. 117 
2. BMI: this variable was estimated by dividing each patient’s weight by height2 (Kg/m2). 118 
3. Hirsutism: hirsutism scoring was based on the Gallway scale (1961). Hutch et al.(16) modified 119 
this scoring system and limited it to 9 androgen sensitive areas each area based on the growth of 120 
terminal hair scored from 0-4 (17). A score of 7 or more indicated hirsutism . 121 
4. Acne: Global Acne Grading Scale (GAGS) was assessed to measure acne. This scale considers 122 
six areas of the face, chest and upper back to measure the level of involvement, distribution, 123 
density and pilosebaceous units. Each of the six areas scores from 0-4 with the most severe 124 
lesion in each area determining the score of that area; the score of each region is multiplied by 125 
the factor score. The factor score is calculated according to the area involved: forehead: 2; left 126 
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and right cheek: 2; nose: 1; chin: 1; chest and upper back: 3. The total score is obtained by 127 
multiplying the factor score by total score of involved area (18). 128 
5. Evaluation of cervical incompetence: transvaginal ultrasound from 16-24 weeks’ gestation was 129 
performed by a gynecologist. The mean cervical length from 16-24 weeks of pregnancy is 25 130 
mm. Cervical length < 25 mm does not indicate cervical incompetence but it is a risk factor for 131 
adverse pregnancy outcomes. Cervical incompetence indicates preterm delivery due to passive 132 
dilation of the uterine cervix. Cervical length < 25 mm is an indication for cerclage placement in 133 
a population of pregnant women with a history of preterm delivery.  In this study we considered  134 
6. cervical length <25 mm as cervical incompetence  and cervical length >25 mm as not having 135 
cervical incompetence (19). 136 
7. Pregnancy-Unique Quantification of Emesis/Nausea (PUQE) Index: The three PUQE questions 137 
each have a rating from 1–5, thus the composite sum ranged from 3–15. A score between 3–6 138 
points was defined as mild, 7–12 points as moderate and scores ≥13 points was classified as 139 
severe nausea and vomiting. Reliability and validity of the questionnaire is approved (20). 140 
 141 
Laboratory measure 142 
An overnight 8-12 hours fasting venous blood sample was obtained from each patient. Serum 143 
total testosterone (TT), sex hormone-binding globulin (SHBG), follicle-stimulating hormone 144 
(FSH), and luteinizing hormone (LH), thyroid stimulating hormone (TSH) and prolactin (PRL) 145 
were concomitantly assessed in all participants by ELISA (DRG Instruments GmbH, Marburg, 146 
Germany). TT and SHBG were used to calculate the free androgen index (FAI). FAI was 147 
estimated as TT (nmol/l)/SHBG (nmol/l) ×100. Except for amenorrhoeic women, all laboratory 148 
determinations were performed in the early follicular phase (3-day menstruation) of the cycle. In 149 
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amenorrhoeic women, after roll out of pregnancy the all laboratory determinations were 150 
performed.  151 
What does this mean? Because amenorrhea may be related to pregnancy that the hormonal 152 
profile will be different with non pregnancy. 153 
 154 
Data analysis 155 
In the present study, we used descriptive and analytic statistics using SPSS 21. Data are 156 
presented as mean (standard deviation) for quantitative variable and n (%) for qualitative 157 
variable. The normality of the distributions was tested using the Kolmogrov-Smirnov test. In 158 
order to make comparison between groups, a t- test was used for quantitative and Mann-Whitney 159 
test for ordinal variables. For comparison between phenotypes of PCOS, the ANOVA test was 160 
used for quantitative and Kruskal-Wallis test for ordinal variables. Linear regression (for neonate 161 
weight) and logistic regression (for preeclampsia and diabetes) were used to determine the most 162 
important predictors.  163 
Univariate and stepwise multiple logistic regression analysis were used to evaluated risk factors 164 
associated with above outcomes (significant differences related to these outcome between 165 
different phenotypes of PCOS).  The analysis of risk factors was concluded in two steps. All the 166 
socioeconomic and characteristics of patients presented in Table 1 were tested one by one in 167 
separate, univariate analysis. Secondly, all statistically significant variables in the univariate 168 
analysis were tested using multivariable logistic regression analysis. Significant variable were 169 
entered in a stepwise manner. Results from the final model are presented as odd ratio with 95% 170 
confidence interval.  The information entered to the regression models was limited to women 171 
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with PCOS (significant differences related to these outcomes between different phenotypes of 172 
PCOS). A significance level of 0.05 was acceptable.  173 
 174 
Ethics  175 
The ethics committee of Kashan University of Medical Sciences approved the present study. All 176 
women gave written inform consent. 177 
 178 
Findings 179 
1. Baseline characterize of participant 180 
Demographic and reproductive characteristics of participants are presented in Table 1. The 181 
results show that significant differences between PCOS and control groups in terms of acne score 182 
(3.62±4.80 vs. 1.82±4.08; P=0.05), hirsutism score (3.18±4.25 vs. 1±2.31; P=0.003), 183 
irregularities menses (P<0.001), testosterone levels (1.02±0.52 vs. 0.65±0.43; P=0.05), SHBG 184 
(146.66±2.29 vs. 120.50±3.24; P=0.05), FAI (10.21±34.45 vs. 4.71±1.70; P=0.02) were 185 
observed. 186 
 187 
2. Obstetric and neonatal status between PCOS and control patients 188 
Table 2 compares pregnancy, delivery and neonatal outcomes between the two groups. Results 189 
show that significant differences between the two groups in the incidence of pre-eclampsia 190 
(P=0.05), gestational diabetes (P=0.05) and birth weight (P=0.05) were observed. It should be 191 
noted that there are any IUGR and LGA in two groups. 192 
 193 
3. Obstetric and neonatal outcome between different phenotypes of PCOS 194 
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Results of Table 3 show the comparison of pregnancy, delivery and neonatal outcomes among 195 
women with different PCOS phenotypes. Significant differences related to pre-eclampsia 196 
(P=0.05), gestational diabetes (P=0.05) and birth weight (P=0.05) between the three PCOS 197 
phenotype were observed. HA + M + PCO phenotype have a higher frequency of pre-eclampsia 198 
and gestational diabetes and lower birth weight of neonates than other phenotypes respectively. It 199 
should be noted that there are any IUGR, LGA and PROM in any of the three groups.  200 
 201 
4. Predictive factors of obstetric and neonatal outcome 202 
The regression results showed that high BMI (β=2.40; CI=1.02-1.58) and increased FAI 203 
(β=13.71; CI=13.71-76.07) were the strongest predictors of pre-eclampsia and diabetes in 204 
patients with PCOS (Data not shown). Moreover, the regression results show that the increase in 205 
FAI (β=3.02; CI=- 20.86, -66.91) was the strongest predictor of weight babies were born to 206 
mothers with PCOS. 207 
 208 
Discussion 209 
This study aimed to assess the pregnancy, delivery and neonatal outcomes in women with PCOS 210 
compared to controls. Results of the study show a higher incidence of pre-eclampsia and 211 
diabetes, and lower weight infants in women with PCOS compared to the control group. Similar 212 
to our findings, in a study conducted by Bjercke et al.(9), the results showed that the prevalence 213 
of pre-eclampsia was higher significantly in women with PCOS (13.5%) compared with the 214 
control group (7%). The prevalence of gestational diabetes in women with PCOS (7.7%) was 215 
higher compared with control (0.6%). The results from Roos et al.(21) also show significantly 216 
increased prevalence of gestational diabetes and pre-eclampsia in women with PCOS compared 217 
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with the control group. Although the study of Palomba et al.(14), the prevalence of gestational 218 
diabetes in PCOS lower than the control group and M + PCO phenotype of PCOS had the 219 
highest prevalence. Roos et al. and Bjercke et al. not cited in literature review or background: 220 
this was cited in background as whole. 221 
 222 
Despite the high prevalence of gestational diabetes mellitus in patients with PCOS compared to 223 
control in the study, the fetal macrosomia was expected.  But, the birth weight in PCOS was less 224 
than the control group especially phenotype HA + M + PCO. This finding may be due to the 225 
incompetence of the placenta in these women who tend to have a high incidence of pre-226 
eclampsia. In a recent review, Qin et al.(15) have proposed there is no definite risk factor for 227 
adverse pregnancy complications in women with PCOS identified as yet. But, Veltman-Verhulst 228 
et al.(22) found that low level of SHBG predicts GDM in women with PCOS. It has been 229 
suggested that FAI is a better and more accurate indicator to measure abnormal androgen level 230 
(23). In the present study, testosterone and SHBG levels were evaluated to assess the FAI. The 231 
results showed that the FAI level was the strongest predictor of gestational diabetes and weight 232 
loss of babies in patients with PCOS. 233 
Previous studies have shown that insulin resistance in PCOS could play a role in the 234 
pathogenesis of pre-eclampsia (9). Although in the current study, the level of insulin resistance 235 
was not measured, the relationship between insulin resistance and androgen levels in non-236 
pregnant women with PCOS has already been demonstrated (24). Introducing higher BMI as the 237 
strongest predictor of pre-eclampsia in the present study and increased levels of androgens in 238 
fatty status is approved this finding. Moreover, in regard to the high incidence of the above 239 
outcomes in HA+M+PCO phenotypes of PCOS, it should be noted that previous studies have 240 
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shown that androgen levels in this phenotype of  PCOS women was higher than other 241 
phenotypes and more prone to metabolic complications. In other words, biochemical 242 
hyperandrogenism plays an essential role in metabolic changes and non-androgenic phenotypes 243 
of PCOS are at a reduced risk of metabolic adverse effects than other phenotypes (25-26). 244 
This study is not without limitations. Participants were selected using a simple sampling method. 245 
The present study is limited to the women recruited from the only referral hospital for infertility 246 
on Kashan, Isfahan, Iran; this may limit the generalizability of our findings.  However, it should 247 
be noted that the women in previous studies were also undergoing infertility treatments that had 248 
different endocrine characteristics and pregnancy outcomes. The merit of the present study is that 249 
all women had a spontaneous pregnancy. Moreover, PCOS diagnosis was confirmed by a 250 
physician experienced in the clinic. All women were first gravidity. 251 
 252 
Conclusions 253 
The results of the present study suggest that PCOS is a risk factor for adverse outcomes in 254 
pregnancy and neonatal including GDM, pre-eclampsia and weight of newborn. These results 255 
were significantly higher in phenotype HA + M + PCO than other phenotypes. Further 256 
prospective studies with bigger sample and different Iranian population are needed to confirm 257 
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Table 1. Demographic and clinical characterizes in participants  












0.56 25.53±4.14 25.03±9.31 24.41±3.49 24.30±6.25 Age ** 
0.60 13.19±3.04 11.04±4.92 11.63±4.11 12.69±3.05 Education ** 
0.05£¥ 
 
1.82±4.08 6.83±1.10 6.58±2.30 6.93±1.38 Acne score** 
0.003£¥ 
 
1±2.21 9.40±0.18 11.17±0.01 11.03±0.31 Hirsutism score** 
0.09 24.34±3.99 24.42±2.34 23.43±7.11 25.80±6.53 BMI (kg/m2)** 
<0.001£¥ 
 
1(2.1) 4(7.01) 5(7.57) 2(3.77) <21 day Menstr
uation 
* 
44 (93.6) 30(52.63) 28(42.42) 22(41.50) 21-35 day 
2 (4.3) 9(15.78) 18(27.27) 15(28.30) 35-60 day 
- 9(15.78) 8(12.12) 6(11.32) 190 day 





117.16±10.67 Systolic blood 
pressure in 6-10 
weeks of 
pregnancy** 
0.25 75.42±8.58 73.37±8.43 71.24±8.74 76.39±8.33 Diastolic blood 
pressure in 6-10 
weeks of 
pregnancy** 
0.93 87.40±7.61 88.12±7.21 87.62±9.11 86.52±8.12 FBS in 6-10 weeks of 
pregnancy** 
0.66 12.68±0.99 12.59± 0.89 12.03± 0.98 12.31± 0.59 Hb in 6-10 weeks of 
pregnancy** 




0.65±0.45 1.02±0.52 1.0±0.12 1.43±0.12 Testosterone 
(nmol/L)** 








54.11±31.10 PRL(IU/l) ** 
0.02£¥ 
 
4.71±1.70 8.22±37.14 8.11±61.41 10.21±34.45 FAI** 
0.29 2.61±1.78 2.67±0.92 2.37±0.49 2.90±0.2 TSH(IU/l) ** 
0.80 73.84±1.63 78.69± 3.21 77.84± 3.34 74.65± 2.52 LH (IU/l) ** 
0.34 47.93±20.83 53.82±32.1
2 
56.71±9.76 58.21±26.18 FSH (IU/l) ** 
*N (%), ** Mean±SD   
*ANOVA 
**kruskal wallis test 
§ P<0.05 between PCOS and Non PCOS phenotype;£ P<0.05 between H+PCO and H+PCO+M phenotype; € 
P<0.05 between H+PCO and M+PCO phenotype;¥ P<0.05 between H+PCO+M and M+PCO phenotype 
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Table 2. Comparison the pregnancy, childbirth and neonatal outcomes between PCOS and control 
groups 
 





0.91 1(2.1) 1(2.3) Abortion * 
0.61 2(4.3) 1(2.3) Malformation * 
0.98 1(2.1) 3(7) PIH* 
0.05 1(2.1) 4(9.3) Pre-eclampsia * 
0.05 6(12.8) 8(18.6) GDM* 
0.06 0 3(7) Amniotic fluid in 32-34 weeks of pregnancy* 
0.83 3(6.4) 3(7) Abruption * 
0.97 7(14.9) 6(14) Preterm labor * 
0.18 2(4.3) - PROM* 
0.36 44(93.6) 41(95.3) Moderate  PUQE in 6-10 weeks of pregnancy * 
3(6.4) 2(4.65) Severe  
0.28 46(97.9) 40(93) Moderate  PUQE in 16-20 weeks of pregnancy* 
- 2(4.65) Severe  
0.09 18(38.3) 23(53.5) NVD Delivery type* 
29(61.70) 20(46.51) C/S 
0.05 3124.13±0.11 3065.50±0.49 Weight  Anthropometric 
characterize of neonate** 0.30 48.43±2.11 45.96±2.53 Height  
0.29 34.54±1.74 33.91±1.56 Head circumstance 
0.10 8.86±0.34 8.97±0.16 Neonate’s Apgar in 1 minute ** 
0.20 9.95±0.20 10±0 Neonate’s Apgar in 5 minute** 




Table 3. Comparison the pregnancy, childbirth and neonatal outcomes among different phenotypes of 
PCOS  







0.20 - 1(11) - Abortion * 
0.20 1(10) - - Malformation * 
 2(20) 1(11) 1(4) PIH* 
0.05 4(40) 1(11) 2(9) Preeclampsia*  
0.05 3(30) 1(11) 2(9) GDM* 
0.16 2(20) 1(11) 1(4) Abnormal amniotic fluid in 32-34 
weeks of pregnancy* 
0.49 - 1(11) 2(9) Abruption * 
0.85 1(10) 3(33.33) 2(9) Preterm labor * 
0.20 9(90) 6(66.66) 16(70) Moderate  PUQE in 6-10 weeks 
of pregnancy * 1(10) - - Severe  
0.05 9(90) - - Mild  PUQE in 16-20 weeks 
of pregnancy* 1(10) 5(55.55) 16(70) Moderate 
0.81 6(60) 4(44.44) 8(36.36) NVD Delivery type* 
4(40) 5(55.55) 14(63.63) C/S 
0.05 2280±0.52 2971.87±87.15 2978.66±22.31 Weight  Anthropometric 
characterize of 
neonate** 
0.40 50.61±1.93 48.26±1.43 48.64±3.34 Height  
0.60 34.11±1.13 33.87±1.36 33.82±2.05 Head 
circumstance 
0.49 9±0 8.93±0.25 9±0 Neonate’s Apgar in 1 minute ** 
- 10 10 10 Neonate’s Apgar in 5 minute** 
*N (%), ** Mean±SD   
